Washington University School of Medicine: Lymphoma trials

The registry lists 23 Lymphoma studies with Washington University School of Medicine as lead sponsor. 1 are open to participants now and 8 have results posted.

Early Phase 1 1Phase 1 9Phase 2 10No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic CancersRecruitingNCT07226934Not applicable
• PROactive Evaluation of Function to Avoid CardioToxicityTerminatedNCT03862131Phase 2Results posted
• BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic LymphomaTerminatedNCT02763384Phase 2Results posted
• Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological MalignanciesCompletedNCT02639559Phase 2Results posted
• Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin LymphomaCompletedNCT02098109Phase 2Results posted
• Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for LymphomaCompletedNCT01969435Phase 2Results posted
• EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia LymphomaCompletedNCT01000285Phase 1/2Results posted
• Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With LymphomaCompletedNCT00733824Phase 1/2Results posted
• Lenalidomide in Relapsed or Refractory Classical Hodgkin LymphomaCompletedNCT00540007Phase 2Results posted
• Enhanced Assistance During Radiotherapy for Unmet Essential NeedsCompletedNCT06582849Not applicable
• Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular LymphomaActive, not recruitingNCT05410418Phase 2
• Imaging Apoptosis for Lymphoma Treatment ResponseTerminatedNCT05048732Early Phase 1
• Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic CancersTerminatedNCT04072393Not applicable
• Minimal Residual Disease in Peripheral T-cell LymphomaCompletedNCT03297697
• Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular LymphomaTerminatedNCT03121677Phase 1
• Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT03072771Phase 1
• Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell LymphomaCompletedNCT02728531Phase 1
• Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive LymphomasCompletedNCT02181218Phase 1
• Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell LymphomaCompletedNCT02086604Phase 1
• Phase I/II Study of Abraxane in Recurrent and Refractory LymphomaTerminatedNCT01555853Phase 1
• Evaluate the Efficacy of Armodafinil for Patients With B-cell Lymphoma and Severe FatigueWithdrawnNCT01044004Not applicable
• Genetic Determinations for Side Effects and Response Rate for Patients Receiving Chemotherapy With Diffuse Large Cell LymphomaCompletedNCT00590941Not applicable
• Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous TherapyTerminatedNCT00006220Phase 1/2